Veriheal

JULY 16, 2020

Despite the novelty of its drug policy findings, the document has gone largely unnoticed by reform advocates and the media. The panel, led by Jake Leinenkugel (a presidential nominee), asserted that psychedelics, such as MDMA and psilocybin, as well as cannabis, present promising ways to treat mental health conditions among military veterans.

Research and Development 95

Research and Development Clinical Trials Treatment Compliance 95

Cannabis Law Report

NOVEMBER 22, 2019

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

OCTOBER 5, 2021

Media: media@mymd.com. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

JULY 9, 2021

The Horizons ETFs product family includes a broadly diversified range of solutions for investors of all experience levels to meet their investment objectives in a variety of market conditions. where applicable laws permit such activities. federal law. Please read the full risk disclosure in the prospectus before investing.

Data 105

Data Clinical Trials Decriminalization Hemp 105

MMJ Recs

DECEMBER 22, 2023

The early 2000s marked a turning point with the passage of medical marijuana laws in states like California, followed by a domino effect as other states recognized the potential therapeutic value of cannabis. This prompted some states to take the first steps toward legalizing medical marijuana.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

JUNE 7, 2021

Media Contact: Will Johnson. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Brett Maas. 646-536-7331. brett@haydenir.com www.haydenir.com.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. ” In Vivo Toxicity Assays Completed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

JULY 6, 2021

Professor Johnson also received national media attention for his appearance in the Home Box Office (HBO) original documentary feature, “Addiction”, which won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts and Sciences. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

JANUARY 11, 2019

federal law protects the retail sale of hemp-derived CBD. . Our analysis follows: Hemp-derived CBD is no longer a controlled substance under federal law. The FDA’s position on CBD is unsettled and unsupported by law. While the DEA is now officially out of the hemp regulation business, the U.S.

Hemp 49

Hemp CBD Law Seed-To-Sale 49

Cannabis Law Report

JANUARY 6, 2022

Scott will work closely with the management team to further develop the company’s internal and external communications with a focus on strategy, branding, social media presence and investor communications. Anebulo Pharmaceuticals, Inc. Scott Anderson. Head of Investor Relations and Public Relations. 858) 229-7063. scott@anebulo.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

SEPTEMBER 22, 2021

At 8,000 times the potency of regular CBD, we believe that Supera-CBD shows strong potential as a therapeutic for high-threat diseases and conditions like Alzheimer’s, psychosis, neuropathic pain, addiction, and anxiety. Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

JULY 7, 2021

Media Contact: Will Johnson. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

CannaMD

NOVEMBER 6, 2019

Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. This led to the conclusion that: Medical marijuana laws may ultimately serve to attenuate the consequences of opioid over reliance. Marijuana Preferred Over Pain Pills. million to 11.4

Marijuana 87

Marijuana Patients Clinical Trials Data 87

The Cannigma

JULY 1, 2022

What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? This is because these types of studies control the most variables to ensure that the results that come out of the trial are as reliable as possible. The cannabis research problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

AUGUST 10, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Media Contact: Will Johnson. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Clinical Trials 105

Clinical Trials Pharmaceutical Research and Development CBD 105

Cannabis Law Report

SEPTEMBER 24, 2019

Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. All investor and media enquiries. media enquiries. media enquiries. What about other medical cannabis products? “The

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JULY 24, 2019

Curaleaf CURLF, -7.27% is “illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases,” the FDA wrote. Mental conditions like anxiety, depression, and PTSD.”.

CBD 51

CBD Tincture Pets Chronic Pain 51

Cannabis Law Report

JULY 23, 2019

It should be noted that Freia’s products are currently authorized under the framework of pharmaceutical law and not subject to the evolving, provisional regulation of cannabis. Media – Kellie Coppin: kcoppin@renmarkfinancial.com. This EU pharmaceutical entity is an optimal addition to LGC. Renmark Financial Communications Inc.

Pharmaceutical 45

Pharmaceutical Seed-To-Sale Compliance Compliance 45

The Joint Blog

JULY 25, 2020

Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. FDA on the Marketing of CBD Products The FDA is fully aware that several states have already passed laws allowing the use of CBD products for both recreational and medicinal purposes. CBD is everywhere these days.

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K. II (“ Silver Spike ”).

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

OCTOBER 22, 2021

SPL026 entered clinical trials at the beginning of 2021 and this designation marks an important step forward towards an accelerated drug approval pathway for bringing the benefits of SPL026 to market for patients suffering with MDD.”. Small Pharma initiated a clinical program into DMT-assisted therapy in February 2021.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

SEPTEMBER 1, 2019

The Victorian and New South Wales Governments had both begun clinical trials of cannabis products for children with severe epilepsy and for palliative care, respectively. Minister for Industry and Skills David Pisoni published a media release to mark the occasion, entitled South Australia welcomes cannabis industry leaders.

Clinical Trials 53

Clinical Trials Research and Development Medicine Cultivation 53

Cannabis Law Report

MARCH 29, 2020

among human subjects, legal knowledge of the laws outlined the Cannabis Act should be distributed to all participants ahead of time. With cannabis, every user has a different experience, but the law that applies to everyone is the same. Respondent experience must be central to the research exercise.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

CannaMD

MARCH 8, 2021

1455 proposes a law: Prohibiting qualified physicians from engaging in certain advertising for their practices relating to marijuana for medical use [p.1, Instead of restricting free speech, the FTC recommends parents practice “media literacy.”. Florida H.B. Specifically, H.B. 1, line 4]. 2, line 32]. Why Physician Advertising Matters.

THC 116

THC Research and Development Treatment Patients 116

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. Conclusions. Background.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JULY 15, 2022

Sunshine Coast based Tikun Oceana, formerly known as Medifarm , is now under the control of administrators from Cor Cordis.The company was founded …… Predictably Murdoch media has this behind a paywall if you want to pay to learn more. Different strains for different conditions. Media event date: 27 August 2019.

Medicine 52

Medicine Patients Media Supply Chain 52

Puff Puff Post

SEPTEMBER 16, 2019

Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. RSVP: If you’d like to attend, please RSVP with Lilia Rassoul ( media@santecannabis.ca ). Time: 9:00AM to 5:00PM. ABOUT SANTÉ CANNABIS.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

JULY 12, 2019

The opening of London’s first such clinic follows the opening of Britain’s first medical cannabis clinic in Greater Manchester earlier in the year. Access is clearly in demand from Londoners as there is already a waiting list of 150 patients at the London clinic ahead of its opening.

Epilepsy 40

Epilepsy Medicine Clinical Trials Chronic Pain 40

Puff Puff Post

SEPTEMBER 16, 2019

Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. RSVP: If you’d like to attend, please RSVP with Lilia Rassoul ( media@santecannabis.ca ). Time: 9:00AM to 5:00PM. ABOUT SANTÉ CANNABIS.

Programs 40

Programs Research and Development Education Treatment 40

The Cannigma

APRIL 8, 2021

Any other medication and you’re lawfully entitled to speak to a pharmacist,” explains Dr. Codi Peterson, a clinical pharmacist and medical cannabis professional. The law states, you must be ensured the opportunity to speak with someone like me.” . The law states, you must be ensured the opportunity to speak with someone like me.

Medicine 108

Medicine Cannabinoids Cannabis THC 108

Cannabis Law Report

JUNE 4, 2021

Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Legislative initiatives (introduction and support of changes of laws). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. Media Contact: Eric Schudiske ( eric@s2spr.com ). What we’ve accomplished thus far is only the beginning!”.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

DECEMBER 7, 2021

Radicle ACES, which launched in August and was completed in record time prior to Thanksgiving, employed validated, standardized health indices to gather real-world health outcomes from a diverse population across a variety of ethnicities, age groups, geographies, behavioral habits, and pre-existing health conditions.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52